Nordic pharma Navamedic launches copies of Zyprexa, CellCept; U.S. asthma spending hits $2.5B;

@FiercePharma: Sen. Kohl introduces drug-spending bill. Includes applying Medicaid rebates to Medicare Part B to save up to $44B. Report | Follow @FiercePharma

> Aiming to break the top 5 Nordic generics suppliers, Navamedic has launched its first two copycat products: its version of Eli Lilly's ($LLY) antipsychotic Zyprexa and a copycat form of Roche's organ transplant drug CellCept. News

> An interim analysis found Merck's ($MRK) Isentress outperformed efavirenz in HIV treatment cocktail, measured by the percentage of patients maintaining undetectable virus levels. Merck release

> U.S. spending on asthma drugs quadrupled to $2.5 billion in the decade ending in 2008, as the percentage of children using meds for the condition doubled to 58%. Story

> The U.K.'s cost-effectiveness watchdog backed broader use of Roche's RoActemra in arthritis patients. Article

> European regulators are working on guidelines for animal-derived pharma ingredients to cut the risk of viral contamination. Report

> Amag Pharmaceuticals ($AMAG), which makes the anemia drug Feraheme, asked investors to support its $179 million takeover bid for Allos Therapeutics, despite opposition from MSMB Capital Management. Story

> United Therapeutics is selling $250 million worth of senior notes to finance its stock repurchasing plan. Piece

> CooperVision says it's working to wrap up a recall of 600,000 Avaira Toric contact lenses, spurred by complaints of severe eye pain in users. Report

Biotech News

@FierceBiotech:  Amgen signals looming restructuring of R&D operations. News | Follow @FierceBiotech

@ JohnCFierce: Just off the phone with Vertex's Peter Mueller. Asked him about his thoughts on early-stage development. He laughed and turned on the fire hose of ideas. This is going to be a fun discussion next Wednesday. | Follow @JohnCFierce

@RyanMFierce:  After reading @FierceMedDev's 5 emerging medtech firms report, a Fierce 15 in medical devices makes even more sense. Report | Follow @RyanMFierce

> Anadys gets a boost from positive PhIIb hep C study. Article

> Amgen signals looming restructuring of R&D operations. News

Vaccines News

> Michael J. Fox Foundation bankrolls AFFiRiS Parkinson's vaccine. Article 

> CA law lets tweens make HPV vaccination decisions. News 

> Inovio, VGX ink hep B and C vaccine deal. Item

> HepB vax Heplisav posts positive Ph3 data. Story

> Coridon HSV-2 vaccine shows 100% efficacy. Report

Manufacturing News

> Pain patch maker warned by FDA over validation reporting. Item 

> Genzyme's Ireland site expanded. Article 

> Teva walloped $163M in hepC ruling, doc 'unfit' for trial. Report 

> China assesses illegal drug activities. Story 

> Ex-Genzyme ops chief joins board at bio start-up. News

> Survey: Disposables adoption stymied by lack of standards. Article

And Finally... Blame it on the Black Death: Gene sequencing finds the bacteria is an ancestor of all modern plagues. More

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.